A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID.
WOODBURY, N.Y., Feb. 22, 2024 /PRNewswire-PRWeb/ -- A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID. The study, titled "Hyperbaric Oxygen Effectively Addresses the Pathophysiology of Long COVID: Clinical Review," was authored by the National Medical Director, and the New England Clinical Director of Hyperbaric Medical Solutions, alongside three other esteemed researchers.
The research team, led by Dr. Alan Katz, National Medical Director of Hyperbaric Medical Solutions, and Dr. Rosemary Byrne, New England Medical Director of the same institution, collaborated with three other prominent experts in the field to explore the potential benefits of HBOT in mitigating the lingering effects of the COVID-19 virus.
Hyperbaric Medical Solutions, a leading provider of hyperbaric oxygen therapy, has been at the forefront of treating long COVID patients with positive outcomes. The research builds upon the institution's commitment to advancing medical knowledge and improving patient outcomes through hyperbaric oxygen and other regenerative medicine therapies.
Key findings from the clinical review include:
- Pathophysiological Impact: The research demonstrates how hyperbaric oxygen therapy effectively addresses the underlying pathophysiological impact of long COVID, providing a potential avenue for targeted treatment.
- Symptom Alleviation: HBOT shows promise in alleviating a range of symptoms associated with long COVID, including fatigue, respiratory issues, and cognitive impairment.
- Improved Quality of Life: Patients undergoing hyperbaric oxygen therapy experienced improvements in their overall quality of life, suggesting a positive impact on long-term recovery.
- Safety and Tolerance: The study emphasizes the safety and tolerance of hyperbaric oxygen therapy, making it a viable option for individuals seeking treatments for long COVID.
Dr. Alan Katz commented on the significance of the findings, stating, "This study opens new avenues for exploring hyperbaric oxygen therapy as a potential intervention for long COVID. The positive outcomes observed in our clinical review highlight the need for further research and clinical trials to validate these promising results."
Hyperbaric Medical Solutions remains committed to advancing the understanding and treatment of long COVID. The institution looks forward to continuing its successful treatment of long COVID patients and contributing to the ongoing efforts to address the global impact of the pandemic.
For further information or to request interviews with the research team, please contact:
Dr. Alan Katz
Hyperbaric Medical Solutions
80 Crossways Park Drive
Woodbury, NY 11797
516-774-2747
https://www.hyperbaricmedicalsolutions.com/
About Hyperbaric Medical Solutions:
Hyperbaric Medical Solutions is a leading provider of hyperbaric oxygen therapy, committed to advancing medical knowledge and improving patient outcomes through innovative therapies. With the National Medical Director and New England Medical Director co-authoring the recent clinical review, Hyperbaric Medical Solutions continues to be at the forefront of research and treatment for long COVID.
Media Contact
Alan A. Katz, Hyperbaric Medical Solutions, 1 516-774-2747, [email protected], https://www.hyperbaricmedicalsolutions.com/
SOURCE Hyperbaric Medical Solutions
Share this article